Who are ALT803's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nivolumab + Relatlimab, BAT2206, AK112, Gemcitabine, Cisplatin, TAR-210, AK117 in combination with AK112, AK112, Carboplatin, Paxlitaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alt803.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ALT803 — Competitive Intelligence Brief

ALT803 (ALT803) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor. Area: Oncology.

phase 1 Immune checkpoint inhibitor LAG-3 Oncology Biologic Live · refreshed every 30 min

Target snapshot

ALT803 (ALT803) — Brenda Cooper, MD. Nucleic acid-based immunotherapy

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ALT803 TARGET	ALT803	Brenda Cooper, MD	phase 1	Immune checkpoint inhibitor	LAG-3
Nivolumab + Relatlimab	Nivolumab + Relatlimab	H. Lee Moffitt Cancer Center and Research Institute	marketed	Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination)	PD-1 and LAG-3
BAT2206	BAT2206	Bio-Thera Solutions	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)
AK112, Gemcitabine, Cisplatin	AK112, Gemcitabine, Cisplatin	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy	PD-1 and LAG-3
TAR-210	TAR-210	Janssen Research & Development, LLC	phase 3	Bispecific antibody	PD-1 and LAG-3
AK117 in combination with AK112	AK117 in combination with AK112	Akeso	phase 3	Bispecific monoclonal antibody	PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112)
AK112, Carboplatin, Paxlitaxel	AK112, Carboplatin, Paxlitaxel	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination	PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor class)

Sun Pharma Advanced Research Company Limited · 2 drugs in this class
Brenda Cooper, MD · 1 drug in this class
Grace Therapeutics Inc. · 1 drug in this class
EMS · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Glycotope GmbH · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
HK inno.N Corporation · 1 drug in this class
Hanlim Pharm. Co., Ltd. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALT803 — Competitive Intelligence Brief. https://druglandscape.com/ci/alt803. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab